SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-16-020749
Filing Date
2016-11-03
Accepted
2016-11-03 16:20:36
Documents
53
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mrtx-20160930x10q.htm 10-Q 736564
2 EXHIBIT 10.1 mrtx93016ex101.htm EX-10.1 183803
3 EXHIBIT 31.1 mrtx93016ex311.htm EX-31.1 12408
4 EXHIBIT 31.2 mrtx93016ex312.htm EX-31.2 12986
5 EXHIBIT 32.1 mrtx93016ex321.htm EX-32.1 8364
  Complete submission text file 0001628280-16-020749.txt   3301943

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT mrtx-20160930.xml EX-101.INS 644975
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mrtx-20160930.xsd EX-101.SCH 23090
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mrtx-20160930_cal.xml EX-101.CAL 44733
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mrtx-20160930_def.xml EX-101.DEF 62020
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mrtx-20160930_lab.xml EX-101.LAB 271376
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mrtx-20160930_pre.xml EX-101.PRE 147686
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35921 | Film No.: 161971879
SIC: 2834 Pharmaceutical Preparations